Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UroGen Pharma (URGN) EBITDA: 2015-2024

Historic EBITDA for UroGen Pharma (URGN) over the last 10 years, with Dec 2024 value amounting to -$126.8 million.

  • UroGen Pharma's EBITDA fell 42.40% to -$33.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$164.9 million, marking a year-over-year decrease of 43.34%. This contributed to the annual value of -$126.8 million for FY2024, which is 24.19% down from last year.
  • Latest data reveals that UroGen Pharma reported EBITDA of -$126.8 million as of FY2024, which was down 24.19% from -$102.1 million recorded in FY2023.
  • UroGen Pharma's 5-year EBITDA high stood at -$102.1 million for FY2023, and its period low was -$128.5 million during FY2020.
  • Over the past 3 years, UroGen Pharma's median EBITDA value was -$109.9 million (recorded in 2022), while the average stood at -$112.9 million.
  • In the last 5 years, UroGen Pharma's EBITDA grew by 13.52% in 2021 and then dropped by 24.19% in 2024.
  • Yearly analysis of 5 years shows UroGen Pharma's EBITDA stood at -$128.5 million in 2020, then rose by 13.52% to -$111.1 million in 2021, then rose by 1.13% to -$109.9 million in 2022, then grew by 7.05% to -$102.1 million in 2023, then dropped by 24.19% to -$126.8 million in 2024.